Stryker Co. (NYSE:SYK) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Stryker Co. (NYSE:SYK) have received a consensus rating of “Moderate Buy” from the twenty brokerages that are presently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and sixteen have given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $421.90.

A number of analysts recently commented on the company. Truist Financial increased their price target on Stryker from $409.00 to $413.00 and gave the company a “hold” rating in a research report on Thursday, January 30th. JPMorgan Chase & Co. increased their price objective on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Needham & Company LLC reissued a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Wednesday, January 29th. Royal Bank of Canada increased their price objective on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. Finally, Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $370.00 to $445.00 in a report on Monday, December 2nd.

Stryker Stock Performance

SYK stock opened at $363.79 on Friday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The firm has a market cap of $138.81 billion, a PE ratio of 46.88, a P/E/G ratio of 2.93 and a beta of 0.95. The business has a 50 day moving average of $382.87 and a 200-day moving average of $373.26. Stryker has a 12-month low of $314.93 and a 12-month high of $406.19.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the business earned $3.46 earnings per share. As a group, sell-side analysts expect that Stryker will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.92%. The ex-dividend date is Monday, March 31st. Stryker’s dividend payout ratio is 43.30%.

Insider Activity at Stryker

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Stryker

A number of large investors have recently added to or reduced their stakes in SYK. Assetmark Inc. increased its holdings in shares of Stryker by 30.7% in the third quarter. Assetmark Inc. now owns 1,013 shares of the medical technology company’s stock worth $366,000 after buying an additional 238 shares during the period. Harbour Investments Inc. increased its holdings in shares of Stryker by 4.2% in the third quarter. Harbour Investments Inc. now owns 6,330 shares of the medical technology company’s stock worth $2,287,000 after buying an additional 256 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Stryker in the third quarter worth about $362,000. Aigen Investment Management LP purchased a new position in shares of Stryker in the third quarter worth about $493,000. Finally, Victory Capital Management Inc. increased its holdings in shares of Stryker by 5.6% in the third quarter. Victory Capital Management Inc. now owns 163,822 shares of the medical technology company’s stock worth $59,182,000 after buying an additional 8,745 shares during the period. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.